The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NEPH | +246.79% | -10.73% | -2.24% | -99% |
| S&P | +13.14% | +87.24% | +13.37% | +503% |
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration, Pathogen Detection and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Pathogen Detection segment develops and sells portable, real-time water testing systems designed to provide actionable data on waterborne pathogens in approximately one hour. The Renal Products segment consists of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate, and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
No news articles found for Nephros.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.76M | 35.4% |
| Gross Profit | $2.88M | 36.2% |
| Gross Margin | 60.47% | 0.4% |
| Market Cap | $50.14M | 178.1% |
| Market Cap / Employee | $1.62M | 0.0% |
| Employees | 31 | 0.0% |
| Net Income | $0.34M | 84.2% |
| EBITDA | $0.35M | 45.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.17M | 110.5% |
| Accounts Receivable | $2.66M | 57.4% |
| Inventory | 2.7 | -11.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.77M | -32.9% |
| Short Term Debt | $0.38M | 12.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 12.53% | 21.3% |
| Return On Invested Capital | -29.27% | 11.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.10M | 115.9% |
| Operating Free Cash Flow | $0.10M | 115.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 216.18 | 22.78 | 32.75 | 34.25 | - |
| Price to Book | 1.90 | 2.11 | 4.67 | 5.22 | 136.81% |
| Price to Sales | 1.10 | 1.18 | 2.65 | 2.91 | 118.06% |
| Price to Tangible Book Value | 2.27 | 2.50 | 5.43 | 6.03 | 128.30% |
| Price to Free Cash Flow TTM | 48.51 | 40.85 | 22.15 | 19.21 | - |
| Enterprise Value to EBITDA | 37.30 | 25.59 | 142.73 | 138.52 | 94.10% |
| Free Cash Flow Yield | 2.1% | 2.4% | 4.5% | 5.2% | - |
| Return on Equity | 0.9% | 9.2% | 15.1% | 16.3% | -247.28% |
| Total Debt | $1.41M | $1.33M | $1.24M | $1.15M | -22.65% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
